Clinical Usefulness of a Cell-based Assay for Detecting Myelin Oligodendrocyte Glycoprotein Antibodies in Central Nervous System Inflammatory Disorders

• DOI: 10.3343/alm.2024.44.1.56
• Publication Date: 2023-09-04T14:01:48Z
• Authors: Jin Myoung Seok; Patrick Waters; Mi Young Jeon; Hye Lim Lee; Seol-Hee Baek; Jin-Sung Park; Sa-Yoon Kang; Ohyun Kwon; Jeeyoung Oh; Byung-Jo Kim; Kyung-Ah Park; Sei Yeul Oh; Byoung Joon Kim; Ju-Hong Min
• Keywords: Myelin oligodendrocyte glycoprotein; Optic neuritis; Neuromyelitis Optica

The clinical implications of myelin oligodendrocyte glycoprotein autoantibodies (MOG-Abs) are increasing. Establishing MOG-Ab assays is essential for effectively treating patients with MOG-Abs. We established an in-house cell-based assay (CBA) to detect MOG-Abs identify correlations patients' characteristics.We the CBA using HEK 293 cells transiently overexpressing full-length human MOG, tested it against 166 samples from a multicenter registry central nervous system (CNS) inflammatory disorders, and compared results those Oxford MOG-Ab-based commercial kit. recruited additional characteristics MOG-Ab-associated disease (MOGAD) neuromyelitis optica spectrum disorder (NMOSD).Of tested, 10 positive MOG-Abs, optic neuritis (ON) being most common manifestation (4/15, 26.7%). CBAs agreed 164/166 (98.8%) (κ=0.883, P<0.001); two (2/166, 1.2%) were only in our CBA, scores laboratories correlated well (r=0.663, P<0.001). kit showed one false-negative three false-positive results. presentation at onset differed between MOGAD NMOSD; ON was frequent MOGAD, transverse myelitis NMOSD.The demonstrated reliable can potentially be used evaluate CNS disorders. A comprehensive, long-term study large patient population would clarify significance